Here's Why Biogen Stock Shot Up 28% in October

Shares of Biogen (NASDAQ: BIIB), a giant biopharmaceutical operation, jumped after management told investors the company would reboot aducanumab's development. Enthusiasm for a potential new drug that might slow the progression of Alzheimer's disease (AD) sent this biotech stock 28.3% higher in October, according to data from S&P Global Market Intelligence.